US market closed today. small Monday and big week... 33 sellers work hard for us and big sales news to come $ Good 2023 for us the longs with VPT
Two machines to Germany
good luck to all of us longs with VPT.. . well done Outside of GE (Buyout), we need to hit 15-20 units per QUARTER to break even from a cash flow perspective. 33 people working on more than 4,000 tracks, (without GE). The fundamental has never been so strong. VMS3.0 has finally ticked all the boxes for REAL Cardiologists. Stories like getting a precise result for a heart the size of a grape - you can't make these things up. We have the real technology, in the area of unmet medical needs. Be patient and hang in there 20 units per week From his email on Oct 27,2022
"9. Our collaboration with GE Healthcare is moving along at the pace they like to move at. Nothing much we can do about that except move ahead addressing the other 60% of the market GEHC does not service. When GEHC gets going it will be drive sales to their customer base, as well market awareness for everyone of the ability of VMS+ to deliver high-quality data from standard echocardiography. We are gearing up for this quantum jump with a new facility capable of manufacturing 20 units per week or 1,000 units per year."
Dear Friend; Happy New Year.
Attached is today’s News Release. Here is some background: 1. I started as President and CEO of Ventripoint October 1, 2010. So for 12 years, I have given it my all to develop the best analytical tool for echocardiography to improve cardiac diagnostics for everyone everywhere and especially for children. 2. With hundreds of clinical publications and dozens of users, thousands of clinicians now aware of the VMS+ and its capabilities and the Company with a salesforce in Europe and North America to connect with all these potential customers, 2023 should be a breakout year for adoption. 3. Ventripoint is my 7th start-up company and by far the one that has taken the longest to develop a product from a disruptive technology to address an unmet medical need. As you know the products I have touched have been used to extend the lives of 300 million people over the last 35 years and the VMS+ will add to this total as it is adopted worldwide. 4. It is time for me to focus on things where my talents can add the most value. Running an operating company with manufacturing, regulatory, sales and marketing and customer support teams is not one of my skills. 5. Fortunately, for all of us, Alvira has the skill to run such a company and I have full trust in her ability to steer the Company to success. 6. I am not leaving but rather will have an executive focus on strategic issues to expand our clinical partnerships and continue to engage with the shareholders and potential shareholders. 7. Of course, the entire Board will be around to advise Alvira with strategic partnerships like the one we have with GEHC, as well as evaluate new opportunities to build value in the Company. 8. The Company is in an excellent place with new manufacturing facility, a distributor network, cash in the bank and a full sales funnel. 2022 was not the best year for the stock markets with major indices down ~22% and VPT was no exception. With a new year, comes renewed energy and determination. Thank you for you continued support and interest. Regards, Dr. George Adams ICD.D Executive-Chairman